A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors.
Vázquez-Borrego MC, Gupta V, Ibáñez-Costa A, Gahete MD, Venegas-Moreno E, Toledano-Delgado Á, Cano DA, Blanco-Acevedo C, Ortega-Salas R, Japón MA, Barrera-Martín A, Vasiljevic A, Hill J, Zhang S, Halem H, Solivera J, Raverot G, Gálvez MA, Soto-Moreno A, Paez-Pereda M, Culler MD, Castaño JP, Luque RM.
Vázquez-Borrego MC, et al. Among authors: cano da.
Clin Cancer Res. 2020 Feb 15;26(4):957-969. doi: 10.1158/1078-0432.CCR-19-2154. Epub 2019 Oct 17.
Clin Cancer Res. 2020.
PMID: 31624102